Medifoxamine

Summary

Medifoxamine (CHEMBL85231) is an approved small molecule (ATC N06AX13); indicated across 1 condition including depressive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AX13
• Indications: 1 condition
• Chemistry: 257.33 Da · C16H19NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL85231
Name	Medifoxamine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	36109
ATC	N06AX13
Molecular formula	C16H19NO2
Molecular weight	257.33
InChIKey	QNMGHBMGNRQPNL-UHFFFAOYSA-N

SMILES: CN(C)CC(OC1=CC=CC=C1)OC2=CC=CC=C2

IUPAC name: N,N-dimethyl-2,2-diphenoxyethanamine

Also known as: Medifoxamina, Medifoxamine, MEDIFOXAMINE

Patent coverage: 487 distinct patent families (2,204 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
depressive disorder	4	MONDO:0002050	MONDO:0002009

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).